Xencor | XNCR - Beneficio Bruto En Ventas





Beneficio Bruto En Ventas Cambio Fecha
AbbVie USD 14.39B 1.85B 2026-06
Alnylam Pharmaceuticals USD 992.69M 167.68M 2026-06
Amgen USD 5.87B 1.02B 2026-03
Arrowhead Research USD 75.25M 1.52M 2026-06
AstraZeneca USD 12.86B 251M 2026-06
Biogen USD 2.12B 307M 2026-06
Bristol-Myers Squibb USD 9.26B 1.19B 2026-06
Cytokinetics USD 23.03M 3.84M 2026-06
GlaxoSmithKline GBP 6.51B 757M 2026-06
J&J USD 18.55B 6M 2026-09
Karyopharm Therapeutics USD 33.72M 1.13M 2026-03
MacroGenics USD 11.24M 19.87M 2026-03
Merck USD 12.09B 1.24B 2026-03
Novartis USD 11.24B 1.18B 2026-06
Pfizer USD -248M 11.29B 2026-06
Regeneron Pharmaceuticals USD 3.71B 778.2M 2026-06
Roche Holding CHF 22.69B 600M 2026-06
Xencor USD 51.22M 46.7M 2026-06